| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| ln Vitro |
9-amino acid, with a MIC of 8–16 μg/mL, exhibits a remarkable antibacterial activity against Klebsiella pneumoniae[1]. When applied as an adjuvant with RIF, 9-amino acids further reduces their toxicity [1]. However, 9-amino acids (0-64 μg/mL) demonstrated considerable cytotoxicity against normal (LO2, HK2, HMC3) and malignant (HepG2, 786-O, U251) human cell lines.
|
|---|---|
| ln Vivo |
9-Aminoacidine (Aminacrine; 15 mg/kg; subcutaneous injection; single dosage) decreases skin abscesses in a model of subcutaneous abscesses [2].
|
| Animal Protocol |
Animal/Disease Models: 7weeks old ICR female mouse skin subcutaneousabscess model [2]
Doses: 15 mg/kg Route of Administration: subcutaneous injection Experimental Results: A single dose of 15 mg/kg 9-AA diminished the abscess area. A single dose of 15 mg/kg 9-AA or 20 mg/kg rifampicin (RIF) did not Dramatically reduce the viable bacterial load in abscesses. The combination of drugs Dramatically diminished bacterial load by 3.15 log10 CFU/abscess. Wound Infection Model:** Female ICR mice were anesthetized, and a 6-mm diameter wound was created on the shaved dorsal skin. The wound was infected with 50 μL of *K. pneumoniae* suspension (3×10⁸ CFU/mL). Two hours post-infection, an ointment containing 0.5% (wt/wt) 9-aminoacridine (9-AA) and/or 0.5% RIF in a Glaxal Base moisturizing cream was applied topically to the wound. The ointment was replaced at 24 hours. At 48 hours post-infection, mice were sacrificed, wound skin was excised, homogenized, and bacterial loads were quantified by plate counting. [2] **Subcutaneous Abscess Model:** Female ICR mice were anesthetized, and 50 μL of *K. pneumoniae* suspension (9×10⁸ CFU/mL) was injected subcutaneously into the dorsal skin. One hour post-inoculation, drugs were administered via subcutaneous injection at the infection site. For 9-AA alone, a dose of 15 mg/kg was used. For combination therapy, 15 mg/kg 9-AA with 20 mg/kg RIF was used. Liposomal formulations [9-AA(L) or 9-AA plus RIF(L)] were administered at 15 mg/kg (9-AA equivalent) or 7.5/15 mg/kg combinations. Mice were euthanized 24 hours post-treatment, abscesses were excised, homogenized, and bacterial loads were quantified. Skin tissues were also collected for H&E staining. [2] **In Vivo Toxicology:** Female ICR mice were administered a single subcutaneous dose of 15 mg/kg 9-AA or 15 mg/kg 9-AA(L). Control mice received 1% DMSO. After 24 hours, blood was collected for hematological and biochemical analysis (liver, renal, myocardial function biomarkers). Major organs (heart, liver, spleen, lung, kidney) were excised for H&E staining and histopathological examination. [2] |
| References | |
| Additional Infomation |
9-Aminoacridine is a yellow needle-like crystal, readily soluble in ethanol. 9-Aminoacridine is an aminoacridine with a structure in which the hydrogen atom at the 9-position of acridine is replaced by an amino group. It is a fluorescent dye and a topical disinfectant, commonly used in eye drops as an acid salt to treat superficial eye infections. It has various uses, including as an anti-infective agent, disinfectant, fluorescent dye, MALDI matrix material, acid-base indicator, and mutagen. It is an aminoacridine compound and also a primary amino compound. It is the conjugate base of 9-aminoacridine (1+). 9-Aminoacridine is a highly fluorescent anti-infective dye, used clinically as a topical disinfectant and experimentally as a mutagen because it interacts with DNA. It can also be used as an intracellular pH indicator.
|
| Molecular Formula |
C13H10N2
|
|---|---|
| Molecular Weight |
194.24
|
| Exact Mass |
194.084
|
| CAS # |
90-45-9
|
| PubChem CID |
7019
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.268g/cm3
|
| Boiling Point |
413.5ºC at 760 mmHg
|
| Melting Point |
241ºC
|
| Flash Point |
233.2ºC
|
| Index of Refraction |
1.78
|
| LogP |
3.551
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
15
|
| Complexity |
207
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
XJGFWWJLMVZSIG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H10N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1-8H,(H2,14,15)
|
| Chemical Name |
acridin-9-amine
|
| Synonyms |
Aminoacridine NSC-13000 NSC 13000
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~27.5 mg/mL (~141.58 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.75 mg/mL (14.16 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.75 mg/mL (14.16 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1483 mL | 25.7414 mL | 51.4827 mL | |
| 5 mM | 1.0297 mL | 5.1483 mL | 10.2965 mL | |
| 10 mM | 0.5148 mL | 2.5741 mL | 5.1483 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
